Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Neutral 62.9%

Neg 0% Neu 62.9% Pos 0%

Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.